Literature DB >> 6088765

Effects on calmodulin of bepridil, an antianginal agent.

H Itoh, T Ishikawa, H Hidaka.   

Abstract

Using biopharmacological techniques, we determined the effect on calmodulin of bepridil, a Ca++ channel blocker. We used two Ca++/calmodulin-dependent enzymes, Ca++/calmodulin-dependent cyclic nucleotide phosphodiesterase from bovine brain and myosin light chain kinase from chicken gizzard. Bepridil inhibited the calmodulin-induced activation of Ca++/calmodulin-dependent cyclic nucleotide phosphodiesterase and the concentration of this drug producing 50% inhibition (IC50) of this enzyme was 8 microM. There was no significant effect on unactivated Ca++/calmodulin-dependent cyclic nucleotide phosphodiesterase (in the absence of Ca++-calmodulin), up to a concentration of 100 microM. Bepridil inhibited specifically Ca++/calmodulin-dependent phosphorylation of chicken gizzard myosin light chain with an IC50 value of 18 microM. Moreover, this agent produced a marked displacement of [3H]N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, an antagonist that interacts selectively with calmodulin. The influence of bepridil on the dose-response curves of mesenteric arterial strips for CaCl2, norepinephrine and serotonin differed from the influence seen with nifedipine, another Ca++ blocker. Bepridil (100 microM) suppressed the Ca++-induced contraction of saponin-skinned mesenteric arteries and calmodulin (26 microM) reversed partly the relaxant effect of this agent. These results suggest that the effect of bepridil on the cardiovascular system is due not only to its Ca++ channel blocking action but also to a calmodulin antagonistic action.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6088765

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

1.  Alteration of the [Ca(2+)](i)-force relationship during the vasorelaxation induced by a Ca(2+) channel blocker SR33805 in the porcine coronary artery.

Authors:  S Ieiri; K Hirano; J Nishimura; S Suita; H Kanaide
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Blockade by antiarrhythmic drugs of glibenclamide-sensitive K+ channels in Xenopus oocytes.

Authors:  H Sakuta; K Okamoto; Y Watanabe
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

Review 3.  Calcium-channel blockers and anaesthesia.

Authors:  P G Durand; J J Lehot; P Foëx
Journal:  Can J Anaesth       Date:  1991-01       Impact factor: 5.063

4.  Effects of bepridil on ventricular depolarization and repolarization of rabbit isolated hearts with particular reference to its possible proarrhythmic properties.

Authors:  T Osaka; I Kodama; J Toyama; K Yamada
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

5.  Proceedings of the British Pharmacological Society. 18th-20th December 1985. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1986-03       Impact factor: 8.739

6.  Modulation of Na+-Ca2+ exchange in cardiac sarcolemmal vesicles by Ca2+ antagonists.

Authors:  T Hata; N Makino; H Nakanishi; T Yanaga
Journal:  Mol Cell Biochem       Date:  1988-11       Impact factor: 3.396

7.  The effects of felodipine and bepridil on calcium-stimulated calmodulin binding and calcium pumping ATPase of cardiac sarcolemma before and after removal of endogenous calmodulin.

Authors:  J M Lamers; P D Verdouw; J Mas-Oliva
Journal:  Mol Cell Biochem       Date:  1987-12       Impact factor: 3.396

8.  Bepridil opens the regulatory N-terminal lobe of cardiac troponin C.

Authors:  Y Li; M L Love; J A Putkey; C Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

9.  Short- and long-term inhibition of cardiac inward-rectifier potassium channel current by an antiarrhythmic drug bepridil.

Authors:  Fangfang Ma; Hiroki Takanari; Kimiko Masuda; Masaki Morishima; Katsushige Ono
Journal:  Heart Vessels       Date:  2015-10-26       Impact factor: 2.037

10.  Bepridil up-regulates cardiac Na+ channels as a long-term effect by blunting proteasome signals through inhibition of calmodulin activity.

Authors:  L Kang; M Q Zheng; M Morishima; Y Wang; T Kaku; K Ono
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.